Crispr Therapeutics vs Janux Therapeutics
Janux Therapeutics is the larger business, with $10.0m of revenue in fiscal 2025 against $3.5m for Crispr Therapeutics (2.8 times as much). Janux Therapeutics grew faster (-5.6% against -90.6%). Janux Therapeutics kept more of each dollar of sales as profit: a net margin of -1136.3% against -16569.8%. Crispr Therapeutics carries less debt relative to equity (0.0% against 0.0%).
| Latest fiscal year | Crispr TherapeuticsCRSP, 2025 | Janux TherapeuticsJANX, 2025 |
|---|---|---|
| Revenue | $3.5m | $10.0m |
| Revenue growth | -90.6% | -5.6% |
| Net income | −$582m | −$114m |
| Operating margin | -18933.6% | -1576.7% |
| Net margin | -16569.8% | -1136.3% |
| Return on equity | -30.2% | -11.5% |
| Free cash flow | −$346m | −$83.3m |
| Cash | $348m | $52.3m |
| Total debt | $0 | $0 |
| Debt to equity | 0.0% | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | — | 109 |
| Market value | $4.83bn | $1.08bn |
| Price vs our value range | — | — |
| Moat score | 10 (Weak) | 12 (Weak) |
| Insider trades, 12 months | 0 buys, 30 sales | 0 buys, 11 sales |